Seven Eight Capital LP bought a new stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 9,662 shares of the company’s stock, valued at approximately $236,000.
Several other hedge funds also recently bought and sold shares of the business. Hexagon Capital Partners LLC increased its position in shares of Myriad Genetics by 75.3% during the second quarter. Hexagon Capital Partners LLC now owns 1,143 shares of the company’s stock worth $28,000 after acquiring an additional 491 shares during the period. Innealta Capital LLC purchased a new position in Myriad Genetics during the 2nd quarter worth $36,000. Neo Ivy Capital Management bought a new stake in Myriad Genetics during the 2nd quarter valued at $85,000. Quest Partners LLC lifted its holdings in shares of Myriad Genetics by 10,724.5% in the 2nd quarter. Quest Partners LLC now owns 5,304 shares of the company’s stock worth $130,000 after buying an additional 5,255 shares during the period. Finally, Headlands Technologies LLC purchased a new stake in Myriad Genetics in the second quarter worth about $162,000. Institutional investors own 99.02% of the company’s stock.
Myriad Genetics Trading Down 2.6 %
Shares of NASDAQ:MYGN opened at $26.93 on Tuesday. The firm has a market capitalization of $2.44 billion, a price-to-earnings ratio of -9.55 and a beta of 1.92. The business’s 50 day moving average price is $27.50 and its 200-day moving average price is $24.16. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.96 and a quick ratio of 1.78. Myriad Genetics, Inc. has a 1 year low of $13.82 and a 1 year high of $29.30.
Insider Buying and Selling at Myriad Genetics
In other Myriad Genetics news, Director Colleen F. Reitan sold 46,012 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $27.95, for a total transaction of $1,286,035.40. Following the completion of the sale, the director now owns 42,533 shares of the company’s stock, valued at $1,188,797.35. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director Heinrich Dreismann sold 10,000 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $27.05, for a total value of $270,500.00. Following the sale, the director now owns 121,648 shares in the company, valued at approximately $3,290,578.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Colleen F. Reitan sold 46,012 shares of Myriad Genetics stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $27.95, for a total value of $1,286,035.40. Following the completion of the transaction, the director now directly owns 42,533 shares of the company’s stock, valued at $1,188,797.35. The disclosure for this sale can be found here. 2.10% of the stock is owned by insiders.
Analysts Set New Price Targets
Several analysts have issued reports on the company. Scotiabank increased their target price on Myriad Genetics from $29.00 to $34.00 and gave the company a “sector outperform” rating in a research report on Tuesday, August 13th. Jefferies Financial Group reiterated an “underperform” rating and issued a $20.00 target price (down previously from $25.00) on shares of Myriad Genetics in a research note on Monday, June 3rd. TD Cowen increased their price target on shares of Myriad Genetics from $28.00 to $30.00 and gave the company a “hold” rating in a research report on Wednesday, August 7th. JPMorgan Chase & Co. raised their price objective on Myriad Genetics from $17.00 to $20.00 and gave the stock an “underweight” rating in a research report on Wednesday, August 7th. Finally, Piper Sandler lifted their target price on shares of Myriad Genetics from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 13th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $28.91.
Get Our Latest Research Report on MYGN
About Myriad Genetics
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Featured Stories
- Five stocks we like better than Myriad Genetics
- Are Penny Stocks a Good Fit for Your Portfolio?
- The Average 401k Balance by Age Explained
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- The How and Why of Investing in Gold Stocks
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.